Beurs.nl monitor iconMarkt Monitor
  • AEX -24,10 877,42 -2,67%
  • DE40 0,00 22.390,84 0,00%
  • US500^ -209,75 5.458,97 -3,70%
  • US30^ -1.286,90 40.931,00 -3,05%
  • EUR/USD +0,02 1,1051 +2,07%
  • WTI -5,19 66,64 -7,23%
  • Gold spot -27,52 3.106,63 -0,88%

Crucell Terug naar discussie overzicht

Maandag 18 mei

24 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. [verwijderd] 19 mei 2009 09:54
    quote:

    josti5 schreef:

    [quote=aad100]
    en waarom wordt ie steeds weer met een paar aandelen lager gezet? zie daar het nut niet van in. Kan iemand mij helpen?
    [/quote]

    Dat komt door de ijzeren vuist van Ronald Brus en z'n maten.
    Zo tegen de AVA van 6 juni wordt het corset wellicht ietsiepietsie verruimd, teneinde niet al te veel boze (dus lastige) aandeelhouders te moeten ontvangen.
    Waarbij op 7 juni de boel nog strakker dan tevoren aangetrokken wordt, natuurlijk.
    AB

    Want dit flauwekul aandeel, moet inderdaad strak geregisseerd worden.
    " Hulde " aan het MT
  2. [verwijderd] 19 mei 2009 10:23
    quote:

    wilb52 schreef:

    ...dit flauwekul aandeel...
    Dat klinkt al veel beter dan je vorige kwalificatie van dit aandeel. De stijgende lijn lijkt ingezet ;-)
  3. flosz 19 mei 2009 11:12
    quote:

    flosz schreef:

    [quote=gogogoo]
    DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
    [/quote]

    Slide 18
    Progress in antibody titers
    PER.C6® XDTM -> CHO / 25-30 -> 10-15

    Slide 14
    Today’s marketplace

    hugin.info/132631/R/1255970/273863.pdf
    ***************************
    Zie plaatje:
    Typical product titer profile of PER.C6® cells in XD™ process compared to a typical fed-batch profile. Depending on the specific productivity of the clones used in the process, volumetric productivity of > 25 g/L of working volume (35 – 40 g/L in supernatant) is routinely achieved in this process approximately 2 weeks after inoculation.
    *************************
    Nog even iets anders……
    STAR
    The STAR® technology typically yields stable mammalian cell clones that produce 5 to 10 fold higher antibody or other therapeutic proteins as compared to cell clones generated without STAR® technology.
    Crucell’s STAR® technology is useful for increasing production of recombinant antibodies and therapeutic proteins on mammalian cell lines. Currently, more than 90% of all antibodies and therapeutic proteins are produced on derivatives of Chinese hamster ovary cells (CHO-K1 and CHO-DG44). It is therefore important that the technology has been successfully used to increase yield in such cell lines.

    All cells in a human body contain identical DNA, but different types of cells have distinct functions. This is a result of cellular differentiation. Cellular differentiation is driven by the microenvironment during development or regeneration of tissue, which determines what parts of the DNA are either active or repressed. The active or repressed state of the DNA, or so-called gene expression profile, determines which proteins are expressed by the cell and which not.

    Each cell type has its own specific gene expression profile. In order to maintain its identity and function, it is important that the cell maintains its gene expression profile. Epigenetic gene regulation mechanisms play a pivotal role in maintaining the gene expression profile of a cell. Maintenance of gene expression is also important for expression of a gene of interest (antibody or therapeutic protein). However, due to these epigenetic gene regulation mechanisms often the expression of the gene of interest is lost. Crucell has identified DNA elements in the human genome that are able to counteract epigenetic gene repression. These elements are called STAR®-elements. By flanking a gene of interest with STAR®-elements, stable mammalian cell lines can be generated that demonstrate much higher expression of the gene of interest than without STAR®-elements. In this way higher yields of the protein of interest can be obtained.

    V.d. DSM website.

    Achieve unmet yields e.g. 12 g/L for standard IgG based on CHO or 27 g/L for standard IgG based on PER.C6® cell line

    XD® Process a revolution in process technology -- limited investment with huge impact

    Push the cell density in mammalian systems to the max to drive yield improvements in the production of biopharmaceuticals.

    DSM's XD® Technology has been developed to drive yield improvements in the production of biopharmaceuticals. "XD" stands for extreme density, as the process is able to push the cell density within the bioreactor to the max and thereby achieve maximum productivity. XD's ultrahigh yields allow for downsizing of bioreactors and opened avenues for new biopharmaceutical manufacturing concepts.


    Would you like to increase your reactor output without changes to the genetic construct?
    DSM’s XD® process offers the solution:
    • For tripling the yield of your process
    • Extending the capabilities of your fed-batch process/plant
    • Achieve unmet yields e.g. 12 g/L for standard IgG based on CHO or 27 g/L for standard IgG based on PER.C6® cell line
    www.dsm.com/en_US/html/dpp/xD_Technol...

    DSM Biologics’ cGMP facility in The Netherlands has a strong track record with a range of cell lines.

    Our cGMP facility in Groningen, The Netherlands has a strong track record with a range of cell lines, including PER.C6® and CHO. We also have considerable experience using multiple manufacturing and purification techniques, including batch, fed-batch, continuous perfusion, and our proprietary XD® technology. Whether you are poised for preclinical development, clinical trials or commercial production (up to 1000L) our scientists and researchers can bring your project from concept to completion successfully.

    Capabilities:
    • Mammalian manufacturing platforms including CHO and PER.C6® cell lines
    • XD® technology
    • Preclinical, clinical and cGMP commercial manufacturing
    • Batch, fed-batch and continuous perfusion
    • Process development, optimization and scale-up
    • Downstream processing
    • Process validation
    • Purification chromatography
    • Analytical development
    • Integrated secondary manufacturing
    www.dsm.com/en_US/html/dpp/DSMBiologi...
24 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.130
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.264
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.903
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.866
Aedifica 3 927
Aegon 3.258 323.111
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.066
Ahold 3.538 74.353
Air France - KLM 1.025 35.301
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.053
Alfen 16 25.345
Allfunds Group 4 1.520
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.080
AMG 972 134.522
AMS 3 73
Amsterdam Commodities 305 6.747
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 497
Antonov 22.632 153.605
Aperam 92 15.070
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.035 321.017
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.360
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.645
ASML 1.766 110.708
ASR Nederland 21 4.515
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.169
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449